Skip to content

Plasma exchange for HBV-related liver failure: a randomised controlled trial

Plasma exchange for HBV-related liver failure: a randomised controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003392
Enrollment
Unknown
Registered
2013-03-29
Start date
2013-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-related liver failure

Interventions

Sponsors

Department of transfusion, Daping Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with liver failure caused by hepatitis B virus; 2. Both male and female between 18-65 years of ages; 3. Patients voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Liver failure caused by other reasons, such as autoimmune diseases, alcohol, drug and so on; 2. Allergies or patients have an allergy to plasma; 3. Chronic liver failure, CLF; 4. Prothrombin time activity, PTA<=20%; 5. Active bleeding or bleeding tendency obviously, DIC, shock and hemodynamic instability; 6. Previous history of abnormal coagulation function or related blood system disease (e.g. hemophilia, leukemia); 7. Tumor on ultrasonography, CT or MRI examination 8. primary non function liver graft or graft dysfunction 9. Severe problems in other vital organs(e.g. the heart, renal or lungs) 10. Patients with mental disorder or disease; 11. Pregnant or breast-feeding women; 12. Patients already received other artificial liver support system treatment before the study; 13. Participate in other clinical trials within 3 month before the study; 14. Other cases which researchers believe that can not enroll.

Design outcomes

Primary

MeasureTime frame
Mortality;

Secondary

MeasureTime frame
Cost of hospitalization;The occurrence and time of complications;Liver function evaluation using MELD score;Improve biochemical indexes;The clinical symptom improvement;Length of stay;Quality of life;The incidence of adverse reaction;

Contacts

Public ContactAiqing Wen
wsw4668@163.com+86 2368757653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026